Artigos de revistas sobre o tema "Appelists"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Veja os 23 melhores artigos de revistas para estudos sobre o assunto "Appelists".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.
Ernst, Wolfgang, e Ghislain Thibault. "Ce que nous appelions « l’histoire des médias » : l’exercice de l’archéologie médiatique". Communiquer. Revue de communication sociale et publique, n.º 13 (9 de abril de 2015): 91–106. http://dx.doi.org/10.4000/communiquer.1550.
Texto completo da fonteSchmidt, Jürgen W. "Stefan Appelius: Die Spionin. Olga Raue. CIA-Agentin im Kalten Krieg". Das Historisch-Politische Buch (HPB): Volume 67, Issue 3 67, n.º 3 (1 de setembro de 2019): 368–69. http://dx.doi.org/10.3790/hpb.67.3.368.
Texto completo da fonteSergio, Ivan. "Propaganda fascista en Chile: el caso de Cile e Patagonia (1930), de Mario Appelius". Artcultura 23, n.º 43 (24 de dezembro de 2021): 192–209. http://dx.doi.org/10.14393/artc-v23-n43-2021-64092.
Texto completo da fonteBasilone, Linetto. "Through East Asia to the sound of ‘Giovinezza’: Italian travel literature on China, Korea and Japan during the Fascist ventennio". Modern Italy 24, n.º 4 (30 de setembro de 2019): 457–68. http://dx.doi.org/10.1017/mit.2019.52.
Texto completo da fonteBrunetti, Mauro M., e Ermanno Quagiotto. "On a new finding of Euciroa arenosa (Rayneval in Appelius, 1871) for the Lower Pliocene of the Mediterranean Basin (Mollusca Bivalvia Euciroidae)". Biodiversity Journal 12, n.º 4 (30 de dezembro de 2021): 993–96. http://dx.doi.org/10.31396/biodiv.jour.2021.12.4.993.996.
Texto completo da fonteZarca, Bernard. "Proximités socioprofessionnelles entre germains et entre alliés : une comparaison dans la moyenne durée". Population Vol. 54, n.º 1 (1 de janeiro de 1999): 37–71. http://dx.doi.org/10.3917/popu.p1999.54n1.0071.
Texto completo da fonteSingh, Abhay, Sarah Sadek, Mark G. Faber, Jeffrey Baron, James E. Thompson, Amanda Przespolewski, Elizabeth A. Griffiths, Eunice S. Wang e Swapna Thota. "The Ever-Changing Therapeutic Landscape of AML: A Real World Experience of Novel Therapies on Outcomes". Blood 134, Supplement_1 (13 de novembro de 2019): 5095. http://dx.doi.org/10.1182/blood-2019-132040.
Texto completo da fonteVachhani, Pankit, Kyle Wiatrowski, Pragya Srivastava, Lisa King, Jody Manischewitz, Hana Golding, Heather L. Bashaw et al. "Quantification of Humoral Immune Response to Influenza Vaccination in MDS". Blood 134, Supplement_1 (13 de novembro de 2019): 4756. http://dx.doi.org/10.1182/blood-2019-126176.
Texto completo da fonteSrivastava, Pragya, Stephanie Tzetzo, Eduardo Cortes Gomez, Kevin Eng, Prashant K. Singh, Kitty De Jong, Sheila N. J. Sait et al. "Inhibition of LSD1 in Myelodysplastic Syndrome Progenitors Restores Differentiation of CD141Hi Conventional Dendritic Cells". Blood 134, Supplement_1 (13 de novembro de 2019): 1695. http://dx.doi.org/10.1182/blood-2019-126220.
Texto completo da fonteBaron, Jeffrey, Christina L. Lombardi, Han Yu, Amanda Przespolewski, Elizabeth A. Griffiths, James E. Thompson, Swapna Thota e Eunice S. Wang. "Benefits of a Pharmacist Led Oral Chemotherapy Monitoring Program for Patients with Chronic Myeloid Malignancies: A Patient Reported Outcome (PRO) Study". Blood 134, Supplement_1 (13 de novembro de 2019): 3501. http://dx.doi.org/10.1182/blood-2019-131629.
Texto completo da fonteThota, Swapna, Abhay Singh, Sarah Sadek, Mark G. Faber, Jeffrey Baron, Amro Elshoury, James E. Thompson, Amanda Przespolewski, Elizabeth A. Griffiths e Eunice S. Wang. "Outcomes of AML Patients Treated with Gemtuzumab-Ozogamicin Based Therapies: A Cue to Optimal Chemotherapy Backbone". Blood 134, Supplement_1 (13 de novembro de 2019): 2645. http://dx.doi.org/10.1182/blood-2019-131633.
Texto completo da fonteWang, Youjin, Weiyin Zhou, Lisa J. McReynolds, Elizabeth A. Griffiths, Swapna Thota, Mitchell Machiela, Stephen J. Chanock et al. "De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Transplant Blood Samples". Blood 134, Supplement_1 (13 de novembro de 2019): 1430. http://dx.doi.org/10.1182/blood-2019-129110.
Texto completo da fontePandey, Manu, Mahesh Swaminathan, Elizabeth A. Griffiths, James E. Thompson, Amanda Przespolewski, Swapna Thota, Jeffrey Baron, Tara L. Cronin e Eunice S. Wang. "Outcomes of Venetoclax-Based Regimens Compared with Hypomethylating Agents (HMA) Alone or 7+3 in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): A Single Center Retrospective Analysis". Blood 134, Supplement_1 (13 de novembro de 2019): 3866. http://dx.doi.org/10.1182/blood-2019-132123.
Texto completo da fontePrzespolewski, Amanda, Craig W. Freyer, Wenyan Ji, Tara L. Cronin, Swapna Thota, Elizabeth A. Griffiths, James E. Thompson et al. "Cladribine, Cytarabine, Granulocyte Colony Stimulating Factor ± Mitoxantrone (CLAG ± M) Is Highly Effective Therapy for Secondary and Relapsed/Refractory Acute Myeloid Leukemia". Blood 134, Supplement_1 (13 de novembro de 2019): 1361. http://dx.doi.org/10.1182/blood-2019-130582.
Texto completo da fonteNavada, Shyamala C., Guillermo Garcia-Manero, Ehab L. Atallah, M. Nabeel Rajeh, Jamile M. Shammo, Elizabeth A. Griffiths, Samer K. Khaled et al. "Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)". Blood 134, Supplement_1 (13 de novembro de 2019): 566. http://dx.doi.org/10.1182/blood-2019-131676.
Texto completo da fonteWang, Eunice S., Elizabeth A. Griffiths, Roland B. Walter, Martin S. Tallman, Aaron D. Goldberg, Boo Messahel e Richard M. Stone. "Tolerability and Efficacy of Crenolanib and Cytarabine/Anthracycline Chemotherapy in Older Patients (Aged 61 to 75) with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML)". Blood 134, Supplement_1 (13 de novembro de 2019): 3829. http://dx.doi.org/10.1182/blood-2019-130536.
Texto completo da fonteIssa, Jean-Pierre, Marco Gobbi, Patricia L. Kropf, Pierre Fenaux, Gail J. Roboz, Jiri Mayer, Jürgen Krauter et al. "Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study". Blood 134, Supplement_1 (13 de novembro de 2019): 4235. http://dx.doi.org/10.1182/blood-2019-129614.
Texto completo da fonteGriffiths, Elizabeth A., Hagop M. Kantarjian, Casey L. O'Connell, Karen W. L. Yee, Wendy Stock, Naval G. Daver, Elias Jabbour et al. "Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients". Blood 134, Supplement_1 (13 de novembro de 2019): 1319. http://dx.doi.org/10.1182/blood-2019-131394.
Texto completo da fonteRoboz, Gail J., Hartmut Döhner, Marco Gobbi, Patricia L. Kropf, Jiri Mayer, Jürgen Krauter, Tadeusz Robak et al. "Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles". Blood 134, Supplement_1 (13 de novembro de 2019): 2591. http://dx.doi.org/10.1182/blood-2019-127253.
Texto completo da fonteGarcia-Manero, Guillermo, James McCloskey, Elizabeth A. Griffiths, Karen W. L. Yee, Amer M. Zeidan, Aref Al-Kali, Kim-Hien Dao et al. "Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine". Blood 134, Supplement_1 (13 de novembro de 2019): 846. http://dx.doi.org/10.1182/blood-2019-122980.
Texto completo da fonteYee, Karen W. L., Gail J. Roboz, Casey L. O'Connell, Elizabeth A. Griffiths, Raoul Tibes, Katherine J. Walsh, Wendy Stock et al. "Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response". Blood 134, Supplement_1 (13 de novembro de 2019): 3846. http://dx.doi.org/10.1182/blood-2019-129845.
Texto completo da fonteWang, Michael, Jacqueline C. Barrientos, Richard R. Furman, Matthew Mei, Paul M. Barr, Michael Y. Choi, Sven de Vos et al. "VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma". Blood 136, Supplement 1 (5 de novembro de 2020): 13–14. http://dx.doi.org/10.1182/blood-2020-136373.
Texto completo da fonteSavona, Michael R., Hagop M. Kantarjian, Gail J. Roboz, Casey L. O'Connell, Katherine J. Walsh, Raoul Tibes, Karen W. L. Yee et al. "Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best Achieved with Adequate Treatment Duration". Blood 134, Supplement_1 (13 de novembro de 2019): 2957. http://dx.doi.org/10.1182/blood-2019-129962.
Texto completo da fonte